Home » Stocks » NVO

Novo Nordisk A/S (NVO)

Stock Price: $69.61 USD 0.39 (0.56%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 163.53B
Revenue (ttm) 20.81B
Net Income (ttm) 6.91B
Shares Out 2.36B
EPS (ttm) 2.46
PE Ratio 28.27
Forward PE 23.36
Dividend $1.23
Dividend Yield 1.76%
Trading Day March 5
Last Price $69.61
Previous Close $69.22
Change ($) 0.39
Change (%) 0.56%
Day's Open 69.24
Day's Range 67.92 - 69.78
Day's Volume 1,322,896
52-Week Range 49.24 - 75.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

Bagsværd, Denmark, 1 March 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...

GlobeNewsWire - 1 week ago

Bagsværd, Denmark, 23 February 2021 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 25 March 2021 at 14:00 (CET)

GlobeNewsWire - 2 weeks ago

Bagsværd, Denmark, 17 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...

GlobeNewsWire - 3 weeks ago

Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...

GlobeNewsWire - 3 weeks ago

Bagsværd, Denmark, 10 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...

Yahoo Finance - 3 weeks ago

Health care: Novo Nordisk CEO discusses 7% sales growth in 2020 and overall industry

Yahoo Finance's Brian Sozzi, Julie Hyman, and Myles Udland speak with Novo Nordisk CEO Lars Jørgensen about the company's healthcare treatments and outlook. #healthcare Subscribe to Yahoo Fina...

GlobeNewsWire - 1 month ago

Bagsværd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associa...

Zacks Investment Research - 1 month ago

Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.

Benzinga - 1 month ago

Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 14.29% year over year to $0.64, which were in line with the es...

Benzinga - 1 month ago

GlobeNewsWire - 1 month ago

Financial report for the period 1 January 2020 to 31 December 2020

GlobeNewsWire - 1 month ago

Bagsværd, Denmark, 2 February 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...

InvestorPlace - 1 month ago

While stocks keep going up and up, more risks are mounting under the surface. As such, you should be looking at safe stocks to buy now.

Other stocks mentioned: ED, HRL, KMB, VZ, WBA, WMT, VZA
GlobeNewsWire - 1 month ago

Novo Nordisk A/S – Share repurchase programme

Zacks Investment Research - 1 month ago

Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.

GlobeNewsWire - 1 month ago

Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing author...

Seeking Alpha - 1 month ago

Novo Nordisk is the global leader in obesity and diabetes treatments. There is evidence that the lockdowns increased the number of people suffering from obesity.

Seeking Alpha - 1 month ago

Novo Nordisk is a well-managed business with long-term growth opportunities. It is the world market leader in diabetes and obesity care.

GlobeNewsWire - 1 month ago

Bagsværd, Denmark, 18 January 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...

Seeking Alpha - 1 month ago

Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

GlobeNewsWire - 1 month ago

Bagsværd, Denmark, 11 January 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...

PRNewsWire - 2 months ago

PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insura...

Seeking Alpha - 2 months ago

In view of the overheated markets, it is worthwhile to take a look at the not so well-trodden paths. However, investors are facing a dilemma. There are a lot of great companies, but only a sma...

Other stocks mentioned: FSNUY, MNHFY
Zacks Investment Research - 2 months ago

Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.

GlobeNewsWire - 2 months ago

Bagsværd, Denmark, 29 December 2020 – Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisati...

GuruFocus - 2 months ago

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.

Other stocks mentioned: ABBV, ABT, LLY, TMO
GlobeNewsWire - 2 months ago

Bagsværd, Denmark, 22 December 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Zacks Investment Research - 2 months ago

Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.

GlobeNewsWire - 2 months ago

Bagsværd, Denmark 18 December 2020 ­– Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for subcutaneous semaglu...

GlobeNewsWire - 2 months ago

Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer's disease with 14 mg oral semaglutide, a once-daily oral formulation o...

GlobeNewsWire - 2 months ago

Novo Nordisk A/S – Share repurchase programme

GlobeNewsWire - 2 months ago

ROSELAND, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced the completion of the previously announced transaction whereby Nov...

The Motley Fool - 2 months ago

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

Other stocks mentioned: BIIB, BNTX, CRSP, EDIT, LLY, RHHBY, SNY
Zacks Investment Research - 3 months ago

Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.

Zacks Investment Research - 3 months ago

Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.

GlobeNewsWire - 3 months ago

Bagsværd, Denmark, 7 December 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...

GlobeNewsWire - 3 months ago

Bagsværd, Denmark, 7 December 2020 – The Danish Maritime and Commercial High Court has ruled that Novo Nordisk's publication of the press release of 19 September 2019:  "Tresiba® showed an ove...

GlobeNewsWire - 3 months ago

Bagsværd, Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 m...

InvestorPlace - 3 months ago

These 7 cheap stocks span industry and have a great chance to appreciate in price next year. Click here for the metrics and reasoning.

Other stocks mentioned: AAN, AFL, CVS, HUM, IBM, INTC
Business Wire - 3 months ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Emispher...

Seeking Alpha - 3 months ago

Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - Transcript

GlobeNewsWire - 3 months ago

Novo Nordisk A/S – Share repurchase programme

Zacks Investment Research - 3 months ago

Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

GlobeNewsWire - 3 months ago

Bagsværd, Denmark, 23 November 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Zacks Investment Research - 3 months ago

Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.

Zacks Investment Research - 3 months ago

Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.

Other stocks mentioned: GILD
GuruFocus - 3 months ago

Danish pharmaceutical giant Novo Nordisk AS (NYSE:NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.

Investors Business Daily - 4 months ago

Novo Nordisk, trading near record highs, early Friday announced it would buy a maker of proprietary oral drug delivery technology, a longtime partner, for $1.8 billion, and NVO stock rose. The...

GlobeNewsWire - 4 months ago

Bagsværd , Denmark, 6 November 202 0 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...

GlobeNewsWire - 4 months ago

ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk ...

About NVO

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a... [Read more...]

Industry
Biotechnology
Founded
1923
CEO
Lars Fruergaard Joergensen
Employees
44,723
Stock Exchange
NYSE
Ticker Symbol
NVO
Full Company Profile

Financial Performance

In 2020, NVO's revenue was 126.95 billion, an increase of 4.04% compared to the previous year's 122.02 billion. Earnings were 42.14 billion, an increase of 8.18%.

Financial numbers in millions DKK.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for NVO stock is "Hold." The 12-month stock price forecast is 79.96, which is an increase of 14.87% from the latest price.

Price Target
$79.96
(14.87% upside)
Analyst Consensus: Hold